



Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Sunao Manabe, Representative Director, President and CEO

(Code no.: 4568, First Section, Tokyo Stock Exchange)

Please address inquiries to Junichi Onuma,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<https://www.daiichisankyo.com>

Correction to “Reference Data (Consolidated Financial Results for Q3 FY2019)”

Tokyo, Japan (February 3, 2020)– Daiichi Sankyo Company, Limited today announced a revision as follows to “Reference Data (Consolidated Financial Results for Q3 FY2019)” materials originally disclosed at 1:00pm on Friday, January 31, 2020.

Correction

Page2 2. Revenue of Global Products

- FY2019 Forecast (as of Oct.) for Trastuzumab Deruxtecan

	Forecast (as of Oct.)	Forecast (as of Jan.)	vs Forecast (as of Oct.)
Before:	<u>JPY - Bn</u>	JPY 12.7 Bn	<u>JPY 12.7 Bn</u>
After:	<u>JPY 9.8 Bn</u>	JPY 12.7 Bn	<u>JPY 2.9 Bn</u>

- FY2019 Forecast (as of Oct.) for Trastuzumab Deruxtecan – Upfront payment

	Forecast (as of Oct.)	Forecast (as of Jan.)	vs Forecast (as of Oct.)
Before:	<u>JPY - Bn</u>	JPY 9.8 Bn	<u>JPY 9.8 Bn</u>
After:	<u>JPY 9.8 Bn</u>	JPY 9.8 Bn	<u>JPY - Bn</u>

Reference Data (Consolidated Financial Results for Q3 FY2019) is available at the following link:

https://www.daiichisankyo.com/media_investors/investor_relations/quarterly_results/index.html